Clinical Trial Goal
To find out if elranatamab is safe and works well to treat multiple myeloma that has relapsed or is refractory
You may be able to join this trial if you:
- Are 18 years old or older
- Have multiple myeloma that has relapsed or is refractory
- Have received 1-3 types of treatment. Your doctor can tell you this
- Have been treated with any of the following. Your doctor can tell you this:
- Anti CD38 monoclonal antibody
- BCMA-directed CAR T-cell therapy
- Immunomodulatory drug (IMiD)
- Proteasome inhibitor
- Do not have any of the following:
- Amyloidosis
- IgM multiple myeloma
- Plasma cell leukemia
- POEMS syndrome
- Smoldering multiple myleoma
- Waldenstrom's macroglobulinemia
- Have not had allogeneic (cells from a donor) blood or marrow transplant (BMT) in the last year
- Have not had autologous (your own cells BMT in the last 3 months
- Agree to have other standard tests done to see if you can be in the clinical trial
Trial Details
Elranatamab is a bispecific T-cell engager (BiTE) therapy that targets BCMA on certain cells.
You’ll get:
You’ll get:
- Elranatamab – Given as a shot under your skin. The dose you'll get depends on when you started the trial and how safe it's been
You'll have biopsies to see how well the treatment is working. The clinical trial doctors will check your health for up to 5 years.
The Food and Drug Administration (FDA) has approved elranatamab to treat multiple myeloma that has relapsed or is refractory after 4 or more types of treatments. Using it in this way to treat multiple myeloma that has relapsed or is refractory after 1-3 types of treatment is new and unproven.
Contacts
Ah-Reum Jeong, (858) 822-6600, ajeong@health.ucsd.edu
Krisma Montalvo, (858) 822-5364, k1montalvo@health.ucsd.edu
Locations
University of California San DiegoRECRUITING
La Jolla, California
Ah-Reum Jeong, MD, (858) 822-5354, CancerCTO@health.ucsd.edu
Sponsors
lead: University of California, San Diego
